Waters Parkerson & CO. LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Waters Parkerson & CO. LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 121,734 shares of the biopharmaceutical company's stock after selling 33,667 shares during the period. Waters Parkerson & CO. LLC's holdings in Pfizer were worth $3,230,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Parsons Capital Management Inc. RI increased its stake in Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after buying an additional 159,984 shares during the period. Mcdonald Partners LLC raised its holdings in Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares in the last quarter. Merit Financial Group LLC lifted its position in Pfizer by 60.8% in the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company's stock valued at $3,395,000 after purchasing an additional 48,397 shares during the period. Bank of Jackson Hole Trust acquired a new position in Pfizer during the 4th quarter worth approximately $264,000. Finally, Amplius Wealth Advisors LLC lifted its holdings in shares of Pfizer by 80.7% in the 4th quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company's stock valued at $1,242,000 after buying an additional 20,911 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE opened at $22.83 on Monday. The company has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a P/E/G ratio of 0.64 and a beta of 0.58. The stock has a 50 day moving average of $23.65 and a 200-day moving average of $25.32. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period last year, the firm posted $0.82 EPS. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.54%. Pfizer's dividend payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.